TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name MAPK pathway inhibitors
Drug Type Not Available
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 115
Pair Name Morusin, MAPK pathway inhibitors
Partner Name Morusin
Disease Info [ICD-11: 2C30] Melanoma Investigative
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Expression BIRC5 hsa332
Down-regulation Expression CCND1 hsa595
Down-regulation Phosphorylation MAPK1 hsa5594
Down-regulation Expression MYC hsa4609
Up-regulation Cleavage PARP1 hsa142
Down-regulation Expression PCNA hsa5111
Down-regulation Expression SOX2 hsa6657
Down-regulation Phosphorylation STAT3 hsa6774
In Vitro Model A-375 Amelanotic melanoma Homo sapiens (Human) CVCL_0132
In Vivo Model A375 and A375R cells (1×10⁵, in 100 μL of phosphate-buffered saline) were subcutaneously injected into the right hind legs of 4-week-old male BALB/c nude mice.
Result Our results suggested that the combination of morusin and MAPK pathway inhibitors may be a more effective treatment strategy for BRAF-mutant melanoma than MAPK pathway inhibitors alone.
03. Reference
No. Title Href
1 Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3. Eur J Cancer. 2022 Apr;165:58-70. doi: 10.1016/j.ejca.2022.01.004. Click
It has been 48291 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP